CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04673240|
Recruitment Status : Unknown
Verified December 2020 by Alessio Baricich, Università degli Studi del Piemonte Orientale "Amedeo Avogadro".
Recruitment status was: Recruiting
First Posted : December 17, 2020
Last Update Posted : December 17, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Spasticity has been defined as a disorder of the sensorimotor system characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex.
The treatment goal of spasticity is Medical treatment generally combines physiotherapy with medications, depending on spasticity distribution. Systemic treatments such as oral or intrathecal baclofen are generally considered in case of generalized spasticity, whereas local treatments are considered in case of focal spasticity.
Local treatments such as Botulinum Toxin type A, phenol, and alcohol present several advantages, allowing to treat of selected muscles without the risk of sedation. As stated above, they are indicated for focal spasticity but might be helpful even in the presence of generalized spasticity with identified focal goals (Bethoux et al., 2015).
In particular, Botulinum Toxin type A (BoNT-A) is considered the gold standard treatment for focal spasticity, showing a level A evidence for spasticity reduction in upper- and lower-limb spasticity (Simpson et al., 2016).
However, current evidence is mainly focused on post-stroke spasticity (Franceschini et al., 2014), whereas it is still limited in spasticity as a consequence of other aetiologies, such as spinal cord injury (SCI), traumatic brain injury (TBI), or multiple sclerosis (MS).
Interestingly, spasticity is a major concern for the rehabilitation of these patients.
The aim of this observational study is the evaluation of the clinical efficacy of BoNT-A in spasticity reduction in patients affected by neurological conditions different from post-stroke spasticity, such as SCI, TBI, and MS.
|Condition or disease||Intervention/treatment|
|Spasticity Brain Injuries Spinal Cord Injuries Multiple Sclerosis||Drug: Botulinum toxin type A injection|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY AFTER TRAUMATIC BRAIN INJURY, SPINAL CORD INJURY OR IN MULTIPLE SCLEROSIS PATIENTS: AN OBSERVATIONAL STUDY|
|Actual Study Start Date :||March 29, 2019|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||June 30, 2022|
- Drug: Botulinum toxin type A injection
Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.
As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician.
- Modified Ashworth Scale (MAS) [ Time Frame: 1 month ]Percentage of patients with at least 1 point reduction of MAS in any treated muscle, 1 month after BoNT-A injection injection of Botulinum toxin A (responders)
- Global Assessment of Efficacy scale) [ Time Frame: 1 month and 3 months after boNT-A injection ]Evaluation of treatment goal achievement by the physicians, patients and caregivers at 1 and 3 months after BoNT-A injection
- active range of motion [ Time Frame: e, 1, 3 and 6 months or before new BoNT-A injection ]Documentation of active range of motion (a-ROM) for the treated joints in the overall study population at baseline, 1, 3 and 6 months or before new BoNT-A injection using a handheld goniometer.
- passive range of motion [ Time Frame: e, 1, 3 and 6 months or before new BoNT-A injection ]Documentation of passive range of motion (p-ROM) for the treated joints in the overall study population at baseline, 1, 3 and 6 months or before new BoNT-A injection using a handheld goniometer.
- Numeric Rating Scale for pain [ Time Frame: , 1, 3 and 6 months after BoNT-A or before the new BoNT-A injection ]Pain will be assessed in the overall study population at baseline, 1, 3 and 6 months after BoNT-A or before the new BoNT-A injection using Numeric Rating Scale (pain).
- EQ5-D [ Time Frame: 1, 3 and 6 months after BoNT-A or before the new BoNT-A injection ]Quality of life will be assessed in the overall study population at baseline, 1, 3 and 6 months after BoNT-A or before the new BoNT-A injection using EQ5-D questionnaire.
- interval of time between BoNT-A reinjections [ Time Frame: 3-6 months ]Documentation of the interval of time between reinjections will be assessed during 6-months follow up (if applicable)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Age >18 years
- Spasticity as a consequence of traumatic brain injury, spinal cord injury or MS (documented by clinical records)
- Muscle tone graded at least 1+ on the modified Ashworth scale in the relevant joints of the affected limb(s), which requires medical intervention
- BoNT naïve or pre-treated with any BoNT product. If previously treated with any BoNT, at least a 4 months interval between last injection and inclusion
- Presence of fixed contractures or bony deformities in the affected limb
- Changes in any oral antispastic medications or specific physiotherapy regimen <4m before study entry or during the study.
- Other neurological or orthopaedic conditions involving the affected limbs.
- Sensitivity to BoNT-A or to its excipients
- Other contraindications as given in the local SmPC for BoNT-A
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04673240
|Contact: Alessio Baricichfirstname.lastname@example.org|
|Contact: Roberta Carozzi||0321 3734805|
|Azienda Ospedaliero Universitaria Maggiore della Carità||Recruiting|
|Novara, Italy, 28100|
|Contact: Alessio Baricich, MDPhD 03213734805 email@example.com|
|Study Chair:||Alessio Baricich||Università del Piemonte orientale "Amedeo Avogadro"|
|Responsible Party:||Alessio Baricich, MD PhD, Università degli Studi del Piemonte Orientale "Amedeo Avogadro"|
|Other Study ID Numbers:||
|First Posted:||December 17, 2020 Key Record Dates|
|Last Update Posted:||December 17, 2020|
|Last Verified:||December 2020|
|Product Manufactured in and Exported from the U.S.:||No|
Spinal Cord Injuries
Wounds and Injuries
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases
Central Nervous System Diseases
Trauma, Nervous System
Spinal Cord Diseases
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action